PMV Pharmaceuticals (PMVP) investor relations material

Executive summary

• Focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations, with lead candidate rezatapopt advancing through clinical trials and NDA submission planned for Q1 2027.

• Completed enrollment for pivotal Phase 2 trial in platinum-resistant/refractory ovarian cancer as part of the PYNNACLE study.

• Rezatapopt received FDA Fast Track and Orphan Drug Designation for TP53 Y220C positive cancers.

• Net loss of $18.1 million for Q2 2026 and $36.1 million for the first half of 2026; accumulated deficit reached $482.6 million as of June 30, 2026.

• No product revenue generated to date; operations funded primarily through equity issuances.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $79.4 million as of June 30, 2026, down from $112.9 million at December 31, 2025.

• Q2 2026 research and development expenses: $14.7 million, down from $18.4 million in Q2 2025, mainly due to lower CRO costs.

• General and administrative expenses: $4.2 million for Q2 2026, compared to $4.5 million in Q2 2025.

• Net loss per share (basic and diluted): $0.34 for Q2 2026, compared to $0.41 in Q2 2025.

• Net cash used in operations was $34.3 million for the first six months of 2026.

Outlook and guidance

• Cash runway expected through Q2 2027; substantial doubt exists regarding ability to continue as a going concern without additional funding.

• Plans to seek accelerated approval for rezatapopt in ovarian cancer and continue advancing pipeline.

• Operating expenses expected to increase as clinical and pre-commercial activities expand.